Spero Therapeutics, Inc., a multi-asset clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, is at the forefront of developing innovative treatments for rare diseases and multi-drug resistant (MDR) bacterial infections. They recently announced that they will share their first quarter 2024 financial results and provide a business and pipeline update on May 15, after the market closes. The company has decided not to host a conference call for this announcement but plans to resume quarterly earnings calls when the second quarter 2024 results are released.
Spero Therapeutics’ lead product candidate, SPR720, is a promising oral first-line treatment for nontuberculous mycobacterial pulmonary disease (NTM-PD). This rare lung disease is caused by non-tuberculous mycobacterial infections. Currently, SPR720 is being studied in a Phase 2A proof of concept trial.
In addition to SPR720, Spero Therapeutics is also developing Tebipenem HBr, an oral drug that is in a Phase 3 registrational trial for the treatment of complicated urinary tract infections, including pyelonephritis. The company has granted GSK an exclusive license to commercialize tebipenem HBr in most territories, excluding certain Asian territories.
Another innovation from Spero Therapeutics is SPR206, an investigational IV-administered direct-acting next-generation polymyxin that demonstrates antibiotic activity against MDR Gram-negative pathogens. This includes carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa, as shown in preclinical studies. The FDA has cleared an Investigational New Drug (IND) application to advance SPR206 into a Phase 2 clinical trial for participants with hospital-acquired or ventilator-associated bacterial pneumonia.
For more information about Spero Therapeutics and their groundbreaking work
